On October 22, 2021, Dilafor has enrolled the first patient in a phase 2a clinical study on the treatment of pregnant women with pre-epilepsy using Tafoxiparin. This exploratory, open-label, randomized, parallel-group, Phase 2a pilot study will assess the safety, tolerability, and efficacy of daily subcutaneous Tafoxiparin therapy up to 4 weeks from the time of diagnosis. The study plans to enroll 23 pregnant women who were diagnosed with pre-epilepsy at 26 to 34 weeks' gestation. Such pregnant women will receive random subcutaneous injections of Tafoxiparin with standard care or only standard care (usually for treatment of the symptoms with antihypertensive drugs).
Tafoxiparin is a patented polysaccharide drug developed by Dilafor. Women who go through a long and complex process of childbirth lack a natural submucosal molecule that plays an important role in childbirth. Preclinical and clinical data show that Tafoxiparin can exert the role of this molecule and can be used in combination with naturally occurring molecules that are extremely important for childbirth.
Dilafor AB is a Swedish drug development company that develops Tafoxiparin adapted to obstetrics. The company's primary goal is to reduce the incidence of slow labour after induction of labour and spontaneous delivery.
The Company entered into a concession agreement with Dilafor AB in February 2014 to manufacture, develop and sell Tafoxiparin adapted for obstetrics and gynecology in Chinese mainland, Hong Kong, China, Macau and Taiwan.